<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115985">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903668</url>
  </required_header>
  <id_info>
    <org_study_id>Ducoroy PHRC IR 2012</org_study_id>
    <nct_id>NCT01903668</nct_id>
  </id_info>
  <brief_title>Determination of the Nature of the Endogenous Ligand of TREM-1 and Its Use as a New Diagnostic Biomarker in Sepsis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>Unspecified</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Step 1: Identification and characterisation of the TREM1L protein from samples already
      available characterised at the hospital Central of Nancy Step 2: Study of the isoforms of
      TREM1L in correlation with the prognosis of sepsis, Step 3: implementation of assay methods
      for TREM1L (ELISA or SUPRA MS) Step 4: Validation of assays for TREM1L and its isoforms in a
      larger number of subjects (inclusion of samples from Dijon CHU and Besan√ßon CHU)
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>plasma concentrations of sTREM-1</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Sepsis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Blood samples used for this study come from a collection being created as part of the
        research entitled &quot;The combined determination STREM-1/PCT/CD64 it allows the diagnosis of
        sepsis in intensive care&quot; - No. IDRCB 2009 - A00870-57 and led by Professor Sebastian
        GIBOT CHU Nancy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients hospitalised in a Medical Intensive Care unit whatever the reason

          -  written informed consent obtained

        Exclusion Criteria:

          -  patients less than 18 years old or under guardianship, persons without national
             health insurance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 17, 2013</lastchanged_date>
  <firstreceived_date>July 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
